ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Carboplatin
Related studies linked through entity extraction aliases.
Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure
- Status
- UNKNOWN
- Phase
- PHASE2
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
- Status
- RECRUITING
- Phase
- PHASE1
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Status
- RECRUITING
- Phase
- PHASE3
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE1/PHASE2
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Myeloprotection With Trilaciclib in Pan-cancer Population
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC
- Status
- TERMINATED
- Phase
- PHASE3
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
- Status
- RECRUITING
- Phase
- PHASE2
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
- Status
- RECRUITING
- Phase
- PHASE2
Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3